Sugi Predict

Sugi Predict / Compounds / SCHEMBL4872950

SCHEMBL4872950

SCHEMBL4872950

O=C(ON1C(=O)CCC1=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ PARL Q9H300 3/20 0.51
▸ PDCD1 Q15116 1/20 0.47
▸ CD274 Q9NZQ7 1/20 0.47
▸ SCN1A P35498 1/20 0.46
▸ SCN2A Q99250 1/20 0.46
▸ SCN3A Q9NY46 1/20 0.46
▸ SLC1A5 Q15758 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ KMT2A Q03164 2/20 0.44
▸ HPGD P15428 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ MGLL Q99685 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ EGFR P00533 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ CTDSP1 Q9GZU7 1/20 0.41
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27444665 0.95 SMN1; SMN2 (0.50) SMN1; SMN2RAB9APARLPDCD1CD274
SCHEMBL13455758 0.93 SMN1; SMN2 (0.44) SMN1; SMN2RAB9APARLPDCD1CD274
SCHEMBL133554 0.90 KMT2A (0.53) SMN1; SMN2RAB9APARLKMT2AMAPK1
SCHEMBL19309377 0.90 KMT2A (0.53) SMN1; SMN2RAB9APARLKMT2AMAPK1
SCHEMBL300884 0.88 CA12 (0.42) SMN1; SMN2RAB9APARLKDM4EKMT2A
SCHEMBL76714 0.87 KMT2A (0.48) SMN1; SMN2RAB9APARLKMT2AHPGD
SCHEMBL14979300 0.87 LMNA (0.45) SMN1; SMN2RAB9APARLKDM4EKMT2A
SCHEMBL15169077 0.87 KMT2A (0.48) SMN1; SMN2RAB9APARLKMT2AMAPK1
SCHEMBL15169078 0.87 KMT2A (0.48) SMN1; SMN2RAB9APARLKMT2AMAPK1
SCHEMBL31539468 0.86 FAAH (0.49) SMN1; SMN2RAB9APARLKMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190866-A1 POLYHYDROXYLATED INDOLIZIDINE AND PYRROLIZIDINE DERIVATIVES AND USES THEREOF ACADEMIA SINICA (TW) 2024-06-13 — — US disclosed
EP-4308108-A1 POLYHYDROXYLATED INDOLIZIDINE AND PYRROLIZIDINE DERIVATIVES AND USES THEREOF Academia Sinica (TW) 2024-01-24 — — EP disclosed
WO-2022197564-A1 POLYHYDROXYLATED INDOLIZIDINE AND PYRROLIZIDINE DERIVATIVES AND USES THEREOF ACADEMIA SINICA (TW) 2022-09-22 — — WO disclosed
EP-2781599-B1 NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN TAGCYX BIOTECHNOLOGIES (JP) 2019-05-08 — — EP disclosed
US-9873879-B2 Nucleic acid fragment binding to target protein TAGCYX BIOTECHNOLOGIES (JP) 2018-01-23 — — US disclosed
US-9873879-B2 Nucleic acid fragment binding to target protein TAGCYX BIOTECHNOLOGIES (JP) 2018-01-23 — — US disclosed
US-9873879-B2 Nucleic acid fragment binding to target protein TAGCYX BIOTECHNOLOGIES (JP) 2018-01-23 — — US disclosed
US-20170073683-A1 NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN TAGCYX BIOTECHNOLOGIES (JP) 2017-03-16 — — US disclosed
US-20170073683-A1 NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN TAGCYX BIOTECHNOLOGIES (JP) 2017-03-16 — — US disclosed
US-20170073683-A1 NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN TAGCYX BIOTECHNOLOGIES (JP) 2017-03-16 — — US disclosed
EP-1436249-B1 MUSCARINIC AGONISTS LILLY CO ELI (US) 2013-11-06 — — EP disclosed
WO-2013073602-A1 NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN 独立行政法人理化学研究所 (JP) 2013-05-23 — — WO disclosed
EP-1608617-B1 MUSCARINIC AGONISTS LILLY CO ELI (US) 2013-01-09 — — EP disclosed
US-7378447-B2 Muscarinic agonists ELI LILLY AND COMPANY (US) 2008-05-27 — — US disclosed
US-7326731-B2 Muscarinic agonists ELI LILLY AND COMPANY (US) 2008-02-05 — — US disclosed
US-20060178438-A1 Muscarinic agonists ELI LILLY AND COMPANY (IN) 2006-08-10 — — US disclosed
US-20060154922-A1 Muscarinic agonists ELILILLY AND COMPANY (US) 2006-07-13 — — US disclosed
EP-1608619-A1 MUSCARINIC AGONISTS ELI LILLY AND COMPANY (US) 2005-12-28 — — EP disclosed
US-20040242584-A1 exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease ELI LILLY AND COMPANY 2004-12-02 — — US disclosed
WO-2004094382-A1 MUSCARINIC AGONISTS ELI LILLY AND COMPANY (US) 2004-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154922-A1 Muscarinic agonists CHRM3, CHRM1, CHRM5 SMN1; SMN2 3032/4885RAB9A 2127/4885PARL 3281/4885
US-20060178438-A1 Muscarinic agonists CHRM3, CHRM1, CHRM5 SMN1; SMN2 3032/4885RAB9A 2127/4885PARL 3281/4885
US-20240190866-A1 POLYHYDROXYLATED INDOLIZIDINE AND PYRROLIZIDINE DERIVATIVES AND USES THEREOF PHKB, BET1, IDO1 SMN1; SMN2 4864/4885RAB9A 2264/4885PARL 244/4885
US-20040242584-A1 exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease CHRM1, CHRM2, CHRM4 SMN1; SMN2 2412/4885RAB9A 1336/4885PARL 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.